Since the start of the pandemic, fear of drug shortages have been top of mind for companies that source active pharmaceutical ingredients from China. A recent FiercePharma article noted that India, the world’s largest maker of generic drugs, is investing in alternatives to Chinese APIs. The Indian government is establishing a $1.3B fund to produce more APIs domestically. The fund will cover infrastructure and financial incentives for up to 20% of incremental sales value over a period of eight years.
Quick Hits: India Weans Itself off Chinese APIs
India is investing $1.3B to decrease its dependence on Chinese APIs amid supply concerns related to the coronavirus outbreak.
Mar 27, 2020
Recommended
Recommended
Researched List: Blister Machines for Life Sciences
Need a blister machine for life sciences packaging? Our curated list features companies serving pharmaceutical, medical device, nutraceutical, and cosmetic industries. Download to access company names, locations, machine specifications, descriptions, and more.
Download Now
Sustainable Healthcare Packaging Solutions That Work
Industry leaders share proven strategies for reducing packaging emissions by up to 70% while meeting safety and regulatory requirements.
Read More
Downloads
